CTAG1A, cancer/testis antigen 1A, 246100

N. diseases: 161; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 AlteredExpression disease BEFREE Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma. 9050879 1997
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 Biomarker disease BEFREE SSX-1 and NY-ESO-1 antigens might be new potentially promising targets for antigen-specific immunotherapy for HCC. 17637219 2007
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 Biomarker disease BEFREE After treatment with 5-aza-CdR, immunoelectron microscopy and Western blotting showed that the HSP70, HLA-I and NY-ESO-1 proteins were increased in exosomes produced by both hepatoma cell lines. 20480522 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 AlteredExpression disease BEFREE The protein levels of NY‑ESO‑1 were detected by immunohistochemistry (IHC) in a tissue microarray (TMA) containing 190 HCC samples. 24085111 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 AlteredExpression disease BEFREE We compared the expression of NY-ESO-1 mRNA in hepatocellular carcinoma (HCC) patients by using various primers and DNA polymerases to optimize RT-PCR conditions and to evaluate the correlations among the expression levels of NY-ESO-1, LAGE-1 and SSX-1 and clinical parameters. 19212631 2009
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.060 Biomarker disease BEFREE Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma. 16872310 2006